Mark Daniels
Pediatric Endocrinology · Orange, CANPI 1568552651
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $524 of the $606 with a category attached, or 86.4%. It is spread thinly across 12 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $181 and has fallen 74.1% since, to $47 in 2025. That places this record below the midpoint for pediatric endocrinology clinicians in CA, where the typical reported total is $615.
Across 24 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$102
- Insulet Corporation$75
- Vistapharm, Inc.$65
- Ascendis Pharma Endocrinology Inc$64
- Pfizer$55
- Amgen$53
- plus $191 from 6 others
Across 52 payments — averaging $5710.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$218K
- Boehringer Ingelheim Pharma GmbH & Co.kg$56K
- Novo Nordisk AS$13K
- Boehringer Ingelheim France S.a.s.$9K
What the payments were for
- Food & beverage$52486%
- Education$325%
- Other$508%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $102 |
| Insulet Corporation | 3 | $75 |
| Vistapharm, Inc. | 3 | $65 |
| Ascendis Pharma Endocrinology Inc | 2 | $64 |
| Pfizer | 3 | $55 |
| Amgen | 2 | $53 |
| Biomarin Pharmaceutical Inc. | 2 | $51 |
| Abbott | 1 | $50 |
| BETA Bionics, Inc. | 1 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Eton Pharmaceuticals, Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$606 in reported general payments places this provider in the 45th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Orange
- Lynda PolgreenOrange$167K
- Timothy FlanneryOrange$32K
- Himala KashmiriOrange$5K
- Daina DreimaneOrange$3K
- Nikita ForghaniOrange$3K
- Lien TrinhOrange$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.